Compositions comprising bacterial strains

Patent metadata

Field	Value
Publication number	US-11446336-B2
Application number	US-202117325502-A
Country	US
Kind code	B2
Filing date	May 20, 2021
Priority date	Dec 12, 2018
Publication date	Sep 20, 2022
Grant date	Sep 20, 2022

Abstract

The invention provides a composition comprising a bacterial strain of the genus Parabacteroides, for use in a method of treating or preventing cancer in a subject; wherein the cancer comprises oncogenic ERK signalling.

First claim

The invention claimed is:

1. A method of treating cancer in a subject in need thereof, comprising administering to the subject a pharmaceutical composition comprising a therapeutically effective amount of a bacterial strain of the species Parabacteroides distasonis , wherein the bacterial strain comprises a 16s rRNA gene sequence having at least 98% sequence identity to the polynucleotide sequence of SEQ ID NO: 9, and wherein the cancer comprises oncogenic ERK signaling, and comprises an oncogenic mutation in, or overexpression of, BRAF, NRAS, ARAF, CRAF, EGFR, GRB2, SOS, HRAS, KRAS, MEK1, MEK2, ERK1 or ERK2.

2. The method of claim 1 , wherein the cancer comprises an oncogenic mutation in BRAF.

3. The method of claim 2 , wherein the oncogenic mutation is at amino acid position 600 in BRAF.

4. The method of claim 2 , wherein the oncogenic mutation is selected from the group consisting of V600E, V600K, V600R, V600D, K601E, G469A, G469V, L597R, K601N, G464V, N581S, L597Q, A598V, G464R, G466A, G469E, and any combinations thereof.

5. The method of claim 1 , wherein the cancer comprises V600E mutation in BRAF.

6. The method of claim 2 , wherein the cancer further comprises overexpression of BRAF.

7. The method of claim 1 , wherein the cancer comprises an oncogenic mutation in NRAS, wherein the oncogenic mutation is Q61R.

8. The method of claim 7 , wherein the cancer further comprises overexpression of NRAS.

9. The method of claim 1 , wherein the cancer comprises an oncogenic mutation in KRAS, wherein the oncogenic mutation is G13D.

10. The method of claim 1 , wherein the cancer comprises colorectal cancer or melanoma.

11. The method of claim 1 , wherein the pharmaceutical composition is formulated for delivery to a gastrointestinal tract of the subject.

12. The method of claim 1 , wherein the therapeutically effective amount comprises from about 1×10 3 to about 1×10 11 colony forming units (CFU).

13. The method of claim 1 , wherein the bacterial strain is the Parabacteroides distasonis strain deposited under accession number NCIMB 42382.

14. The method of claim 1 , wherein the bacterial strain comprises a 16s rRNA gene sequence having at least 99% sequence identity to the polynucleotide sequence of SEQ ID NO: 9.

15. The method of claim 1 , wherein the bacterial strain comprises a 16s rRNA gene sequence of the polynucleotide sequence of SEQ ID NO: 9.

16. The method of claim 1 , wherein the subject is immunocompromised or immunosuppressed.

17. A method of treating cancer in a subject in need thereof, comprising administering to the subject a pharmaceutical composition comprising a therapeutically effective amount of a bacterial strain of the species Parabacteroides distasonis,
wherein the bacterial strain comprises a 16s rRNA gene sequence having at least 98% sequence identity to the polynucleotide sequence of SEQ ID NO: 9, and wherein the cancer comprises oncogenic ERK signaling.

18. The method of claim 17 , wherein the cancer is colorectal cancer or melanoma.

19. The method of claim 17 , wherein the bacterial strain comprises a 16s rRNA gene sequence having at least 99% sequence identity to the polynucleotide sequence of SEQ ID NO: 9.

20. The method of claim 17 , wherein the therapeutically effective amount comprises from about 1×10 3 to about 1×10 11 colony forming units (CFU).

Assignees

• 4D Pharma Res Ltd

Inventors

• MULDER Imke Elisabeth
• Ettorre Anna
• Ahmed Suaad
• Fotiadou Parthena

Classifications

• A61K2035/115

  Probiotics · CPC title

• A61K2039/55511

  Organic adjuvants · CPC title

• A61P35/00

  Antineoplastic agents · CPC title

• A61K35/741 Primary

  Probiotics (probiotic yeast, e.g. saccharomyces A61K36/06) · CPC title

• A61K35/74 Primary

  Bacteria (therapeutic use of a bacterial protein A61K38/00) · CPC title